Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity.
To determine the effects of raloxifene hydrochloride, 60 mg/d, on serum levels of E(2), estrone, sex steroid-binding globulin, thyroxine-binding globulin, and follicle-stimulating hormone (FSH) in postmenopausal women. Randomized placebo-controlled study at 16 centers in the United States. Ninety three women 42 to 80 years of age who were at least 2 years postmenopausal. Raloxifene (n = 47) or placebo (n = 46) for 3 months. Levels of E(2), estrone, sex steroid-binding globulin, thyroxine-binding globulin, and FSH were measured at baseline and after 3 months of therapy. Raloxifene increased serum levels of sex steroid-binding globulin and thyroxine-binding globulin and decreased FSH levels compared with placebo. Levels of E(2) and estrone were unaffected. In postmenopausal women, raloxifene (60 mg/d) did not increase serum estrogen levels; however, it increased levels of sex steroid-binding globulin and thyroxine-binding globulin and decreased FSH levels.